Treatment Resistant Depression
Core Clinical Research is currently conducting numerous research studies looking at investigational medications for adults with Treatment Resistant Depression, TRD.
Treatment Resistant Depression, TRD, can be characterized by the following:
- Having an inadequate response to at least two courses of an adequate antidepressant therapy for your Major Depressive Episode (MDE)
- An adequate antidepressant therapy can be defined as at least four weeks on a therapeutic dose of an FDA approved antidepressant therapy
- An inadequate response to a treatment may be thought of as a less than fifty percent improvement in the symptoms of your major depressive episode
In some cases, TRD research studies permit a history of only one adequate medication trial and in other cases TRD research studies would require a history of two adequate medication trials.
In a TRD research study the participant receives an investigational combination therapy for their major depressive episode.
To qualify for a TRD research study participants must be 18 to 70 years old, currently depressed and currently taking an antidepressant therapy.
If you are an adult whom is currently taking an antidepressant and you have had less than fifty percent improvement in depressive symptoms, you may qualify for a no-cost research study for TRD. Compensation for study time and travel is provided to you.
If you would like to receive a full no cost evaluation from a board-certified psychiatrist, please contact Core Clinical Research. Upon evaluation you may be presented with one or several study treatment options. Participation in a clinical trial is 100% voluntary and at your discretion. There is no cost to participate and you will be compensated for your travel and research study time. Investigational medications will be provided by Core Clinical Research at no cost.
Study treatment options may vary from study medications are that currently already being prescribed to adults in the U.S, to study medications that are only being used for the treatment of other indications, in other countries around the world, or new therapies that have not yet been FDA approved.
Contact Core Clinical Research to see if you qualify for a no-cost comprehensive evaluation for Treatment Resistant Depression